Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
AbbVie Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group Intertiol
AstraZeneca Plc
Dialectic Therapeutics Inc
Siromics Inc
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
ABT-737 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0466 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-2216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitoclax dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pelcitoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-369 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response
Sep 13, 2021: Ascentage Pharma announces latest data of its investigatiol Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Sep 08, 2021: Ascentage Pharma announces latest data of its investigatiol Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Aug 20, 2021: Dialectic Therapeutics receives $14.4 million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas
May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting
Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021
Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216
Feb 09, 2021: AZD0466 clinical DEP program global expansion
Oct 08, 2020: Ascentage Pharma’s apoptosis-targeting drug candidate granted Orphan Drug Desigtion by the US FDA
Jul 27, 2020: AZD0466 trial opens MD Anderson Cancer Center as a site
Jun 23, 2020: Starpharma showcased poster presentation on DEP product AZD0466 at AACR 2020
May 31, 2020: Ascentage Pharma presents latest clinical data of APG-1252 drug candidate at the 2020 ASCO
May 15, 2020: Ascentage Pharma to present data on APG-1252 at 2020 AACR Annual Meeting
Feb 26, 2020: Dialectic Therapeutics receives $3 million seed award for product development research from the Cancer Prevention & Research Institute of Texas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Ascenta Therapeutics Inc, 2021
Pipeline by Ascentage Pharma Group International, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Dialectic Therapeutics Inc, 2021
Pipeline by Sirnaomics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021